Jazz Pharmaceuticals (JAZZ) Short-term Investments (2011 - 2017)
Jazz Pharmaceuticals' quarterly Short-term Investments came in at $200.0 million in Q3 2017, up 236.6% year-on-year from $59.4 million in Q3 2016, and up 150.0% quarter-over-quarter from $80.0 million in Q2 2017.
Jazz Pharmaceuticals has reported Short-term Investments for 4 years, with the latest figure at $200.0 million in Q3 2017.
- For the quarter ending Q3 2017, Short-term Investments rose 236.6% year-over-year to $200.0 million; the trailing twelve-month figure through Sep 2017 stood at $200.0 million (up 236.6% YoY), and the FY2016 full-year result was $60.0 million, changed N/A from the prior year.
- Short-term Investments for Q3 2017 stood at $200.0 million, up from $80.0 million in the prior quarter.
- The five-year high for Short-term Investments was $200.0 million in Q3 2017, with the low at $764000.0 in Q1 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2017 | 200.00 Mn |
| Jun 30, 2017 | 80.00 Mn |
| Mar 31, 2017 | 60.00 Mn |
| Dec 31, 2016 | 60.00 Mn |
| Sep 30, 2016 | 59.42 Mn |
| Jun 30, 2016 | 48.41 Mn |
| Mar 31, 2016 | 764,000.00 |
| Mar 31, 2012 | 73.56 Mn |
| Dec 31, 2011 | 75.82 Mn |
| Sep 30, 2011 | 12.13 Mn |